Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.

Br J Cancer. 2018 May 14. doi: 10.1038/s41416-018-0098-6. [Epub ahead of print]

PMID:
29755120
2.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Mar 5. doi: 10.1093/jnci/djy022. [Epub ahead of print]

PMID:
29514301
3.

Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Pezzolo A, Sementa AR, Lerone M, Morini M, Ognibene M, Defferrari R, Mazzocco K, Conte M, Gigliotti AR, Garaventa A, Pistoia V, Varesio L.

Cancer Biol Ther. 2017 May 4;18(5):285-289. doi: 10.1080/15384047.2017.1312231. Epub 2017 Apr 12.

4.

Piloting the European Unified Patient Identity Management (EUPID) Concept to Facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking.

Ebner H, Hayn D, Falgenhauer M, Nitzlnader M, Schleiermacher G, Haupt R, Erminio G, Defferrari R, Mazzocco K, Kohler J, Tonini GP, Ladenstein R, Schreier G.

Stud Health Technol Inform. 2016;223:31-8.

PMID:
27139382
5.

Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma group.

Mazzocco K, Defferrari R, Sementa AR, Garaventa A, Longo L, De Mariano M, Esposito MR, Negri F, Ircolò D, Viscardi E, Luksch R, D'Angelo P, Prete A, Castellano A, Massirio P, Erminio G, Gigliotti AR, Tonini GP, Conte M.

Pediatr Blood Cancer. 2015 Oct;62(10):1725-32. doi: 10.1002/pbc.25552. Epub 2015 Apr 29.

PMID:
25925003
6.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

7.

Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Passariello A, De Brasi D, Defferrari R, Genesio R, Tufano M, Mazzocco K, Capasso M, Migliorati R, Martinsson T, Siani P, Nitsch L, Tonini GP.

Eur J Med Genet. 2013 Nov;56(11):626-34. doi: 10.1016/j.ejmg.2013.08.005. Epub 2013 Sep 13.

PMID:
24035971
8.

The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B.

Neoplasia. 2012 Jul;14(7):634-43.

9.

Cyto-morphologic evaluation of bone marrow in infants with disseminated neuroblastoma.

Sorrentino S, Rosanda C, Parodi S, Rita Gigliotti A, Pasino M, Defferrari R, Tonini GP, De Bernardi B.

J Pediatr Hematol Oncol. 2012 Mar;34(2):154-8. doi: 10.1097/MPH.0b013e31821d80be.

PMID:
22367387
10.

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J.

Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10.

11.

A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.

12.

Simultaneous tumors: acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma.

Di Cataldo A, Mazzocco K, Magro G, Mirabile E, Lo Nigro L, Defferrari R, Tonini GP.

Pediatr Blood Cancer. 2011 Feb;56(2):298-300. doi: 10.1002/pbc.22807.

PMID:
20973101
13.

MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.

Parodi S, Perfumo C, Garaventa A, Inga A, Mazzocco K, Defferrari R, Tonini GP, Fronza G, Haupt R.

Pediatr Blood Cancer. 2010 Aug;55(2):267-72. doi: 10.1002/pbc.22477.

PMID:
20232446
14.

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.

Pediatr Blood Cancer. 2009 Oct;53(4):576-83. doi: 10.1002/pbc.22132.

PMID:
19526525
15.

Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Haupt R, Fronza G, Tonini GP.

Eur J Cancer. 2008 Nov;44(17):2634-9. doi: 10.1016/j.ejca.2008.08.018. Epub 2008 Oct 1.

PMID:
18835771
16.

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.

Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, McDowell HP, Boldrini R, Dominici C, Tonini GP, Raschellà G, Calabretta B.

Clin Cancer Res. 2008 Jun 1;14(11):3248-53. doi: 10.1158/1078-0432.CCR-07-4725.

17.

Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.

Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP.

Cancer Genet Cytogenet. 2007 Aug;177(1):20-9.

PMID:
17693187
18.

Concomitant DDX1 and MYCN gain in neuroblastoma.

Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, Valent A, Schena F, Perri P, Mazzocco K.

Cancer Lett. 2007 Oct 18;256(1):56-63. Epub 2007 Jul 3.

PMID:
17611020
19.

Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.

Coco S, Defferrari R, Scaruffi P, Cavazzana A, Di Cristofano C, Longo L, Mazzocco K, Perri P, Gambini C, Moretti S, Bonassi S, Tonini GP.

J Pathol. 2005 Nov;207(3):346-57.

PMID:
16178058
20.

Scutular tinea of the scrotum: report of two cases.

Prochnau A, de Almeida HL Jr, Souza PR, Vetoratto G, Duquia RP, Defferrari R.

Mycoses. 2005 May;48(3):162-4.

PMID:
15842330
21.

Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.

Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, Tonini GP.

Mol Diagn. 2004;8(2):93-100.

PMID:
15527323
22.

Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma.

Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP.

Am J Med Genet A. 2003 May 1;118A(4):309-13.

PMID:
12687660
23.

mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit.

Schito AM, Pizzuti A, Di Maria E, Schenone A, Ratti A, Defferrari R, Bellone E, Mancardi GL, Ajmar F, Mandich P.

Neurosci Lett. 1997 Dec 12;239(1):49-53.

PMID:
9547169
24.

MEL-P, a GM-CSF-producing human melanoma cell line.

Ciotti P, Imro A, Scudeletti M, Rainero ML, Defferrari R, Ghiorzo P, Indiveri F, Bianchi-Scarrà G.

Melanoma Res. 1996 Jun;6(3):203-13. Erratum in: Melanoma Res 1996 Aug;6(4):337.

PMID:
8819123
25.

Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion.

Mancardi GL, Mandich P, Nassani S, Schenone A, James R, Defferrari R, Bellone E, Giunchedi M, Ajmar F, Abbruzzese M.

J Neurol Sci. 1995 Jul;131(1):30-4.

PMID:
7561944
26.

Molecular diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) by detection of 17p11.2 deletion in Italian patients.

Mandich P, James R, Nassani S, Defferrari R, Bellone E, Mancardi G, Schenone A, Abbruzzese M, Rocchi M, Ajmar F, et al.

J Neurol. 1995 May;242(5):295-8.

PMID:
7643137
27.

Cytogenetics of the tissue involved in neural tube defects.

Haupt R, Byrne J, Defferrari R, Cama A, Levato L, Lavia N, Vigliarolo MA, Capra V, Andreussi L.

Genet Couns. 1995;6(1):49-53.

PMID:
7794562
28.

Isochromosome 12p-positive pineal germ cell tumor.

de Bruin TW, Slater RM, Defferrari R, Geurts van Kessel A, Suijkerbuijk RF, Jansen G, de Jong B, Oosterhuis JW.

Cancer Res. 1994 Mar 15;54(6):1542-4.

29.

Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists.

Van der Ven LT, Prinsen IM, Jansen GH, Roholl PJ, Defferrari R, Slater R, Den Otter W.

Br J Cancer. 1993 Sep;68(3):475-83.

30.

Molecular analysis of six variant Philadelphia chromosome translocations in chronic myeloid leukemia.

Sessarego M, Martinelli G, Chiamenti A, Defferrari R, Fugazza G, Bruzzone R, Ajmar F, Pignatti PF.

Cancer Genet Cytogenet. 1993 May;67(1):50-4.

PMID:
8504399
31.
32.

Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation.

Sessarego M, Frassoni F, Defferrari R, Bacigalupo A, Fugazza G, Mareni C, Bruzzone R, Dejana A, Ajmar F.

Cancer Genet Cytogenet. 1991 Nov;57(1):69-78.

PMID:
1756487
33.

Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.

Carella AM, Gaozza E, Raffo MR, Carlier P, Frassoni F, Valbonesi M, Lercari G, Sessarego M, Defferrari R, Guerrasio A, et al.

Leukemia. 1991 Jun;5(6):517-21.

PMID:
1676080
34.

Involvement of the short arm of the derivative chromosome 9 in Philadelphia-positive acute lymphoblastic leukemia.

Sessarego M, Defferrari R, Fugazza G, Comelli A, Salvidio E, Ajmar F.

Cancer Genet Cytogenet. 1991 Mar;52(1):43-9.

PMID:
2009511
35.

Cytogenetics of infantile leukemias and its correlations with bio-clinical features. The "G. Gaslini" Children's Hospital experience over a 9-year period.

Haupt R, Comelli A, Garré ML, Defferrari R, Fugazza G, Basso G, Rosanda C, Sessarego M, Sansone R.

Haematologica. 1991 Mar-Apr;76(2):109-12.

PMID:
1937167
36.

Patterns of relapse after bone marrow transplantation for chronic myeloid leukaemia.

Frassoni F, Sessarego M, Martinelli G, Strada P, Gualandi F, Lamparelli T, Pignatti PF, Defferrari R, Fugazza G, Bacigalupo A, et al.

Bone Marrow Transplant. 1991;7 Suppl 2:17-8. No abstract available.

PMID:
1878694
37.

Late-appearing Philadelphia chromosome in acute lymphoblastic leukemia.

Sessarego M, Defferrari R, Dejana A, Salvidio E.

Cancer Genet Cytogenet. 1990 Aug 1;48(1):35-8.

PMID:
2372785
38.

Molecular analysis of Philadelphia-negative myeloproliferative syndromes with i(17q).

Mareni C, Sessarego M, Origone P, Defferrari R, Frassoni F, Ajmar F.

Cancer Genet Cytogenet. 1989 Dec;43(2):195-201.

PMID:
2598164
39.

Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study.

Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F.

Cancer Genet Cytogenet. 1989 Nov;43(1):57-65.

PMID:
2790773
40.

Translocation t(9;9)(p13;q34) in Philadelphia-negative chronic myeloid leukemia with breakpoint cluster region rearrangement.

Sessarego M, Mareni C, Vimercati R, Defferrari R, Origone P, Damasio E, Ajmar F.

Cancer Genet Cytogenet. 1989 Nov;43(1):51-6.

PMID:
2790772
41.

Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia.

Sessarego M, Frassoni F, Defferrari R, Bacigalupo A, Miceli S, Mareni C, Ajmar F.

Cancer Genet Cytogenet. 1989 Oct 15;42(2):253-61.

PMID:
2790760
42.

t(1;7) in acute myeloblastic leukemia following myelodysplastic syndrome (RAEB-T).

Defferrari R, Sessarego M, Santini G, Ajmar F.

Tumori. 1988 Oct 31;74(5):555-8.

PMID:
3217990
43.

Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia.

Frassoni F, Sessarego M, Bacigalupo A, Strada P, Repetto M, Miceli S, Occhini D, Defferrari R, Marmont A.

Br J Haematol. 1988 Aug;69(4):471-5.

PMID:
3044441
44.

Variant Philadelphia translocations in CML: correlation with fragile sites.

Sessarego M, Defferrari R, Panarello C, Frassoni F, Mandich P, Ajmar F.

Cancer Genet Cytogenet. 1988 Mar;31(1):105-12.

PMID:
3125958

Supplemental Content

Loading ...
Support Center